Ignite Creation Date:
2025-12-25 @ 2:09 AM
Ignite Modification Date:
2026-02-25 @ 7:03 PM
Study NCT ID:
NCT02041260
Status:
UNKNOWN
Last Update Posted:
2021-10-15
First Post:
2014-01-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Sponsor:
Thomas Jefferson University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2022-05
Completion Date Type:
ESTIMATED
First Submit Date:
2014-01-17
First Submit QC Date:
None
Study First Post Date:
2014-01-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-10-07
Last Update Post Date:
2021-10-15
Last Update Post Date Type:
ACTUAL